This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Saiki, A. Y. C.
Right arrow Articles by Lerner, C. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saiki, A. Y. C.
Right arrow Articles by Lerner, C. G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 1999, p. 1574-1577, Vol. 43, No. 7
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

DNA Cleavage Activities of Staphylococcus aureus Gyrase and Topoisomerase IV Stimulated by Quinolones and 2-Pyridones

Anne Y. C. Saiki, Linus L. Shen,* Chih-Ming Chen, John Baranowski, and Claude G. Lerner*

Abbott Laboratories, Infectious Disease Research, Abbott Park, Illinois 60064-3537

Received 24 November 1998/Returned for modification 5 January 1999/Accepted 12 April 1999

We have cloned Staphylococcus aureus DNA gyrase and topoisomerase IV and expressed them in Escherichia coli as polyhistidine-tagged proteins to facilitate purification and eliminate contamination by host enzymes. The enzyme preparations had specific activities similar to previously reported values. Potassium glutamate (K-Glu) stimulated the drug-induced DNA cleavage activity and was optimal between 100 and 200 mM for gyrase and peaked at 100 mM for topoisomerase IV. Higher concentrations of K-Glu inhibited the cleavage activities of both enzymes. Using a common buffer system containing 100 mM K-Glu, we tested the enzyme-mediated DNA cleavage activities of both gyrase and topoisomerase IV with oxolinic acid, norfloxacin, ciprofloxacin, trovafloxacin, clinafloxacin, and the 2-pyridone ABT-719. As expected, all drugs tested demonstrated greater potency against topoisomerase IV than against gyrase. In addition, cleavage activity was found to correlate well with antibacterial activity.


* Corresponding author. Mailing address: Abbott Laboratories, Infectious Disease Research, D47P/AP52-1N, 200 Abbott Park Rd., Abbott Park, IL 60064-3537. Fax: (847) 938-3403. Phone for Linus L. Shen: (847) 937-5983. E-mail: linus.l.shen{at}abbott.com. Phone for Claude G. Lerner: (847) 937-7875. E-mail: claude.lerner{at}abbott.com.


Antimicrobial Agents and Chemotherapy, July 1999, p. 1574-1577, Vol. 43, No. 7
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Robertson, G. T., Bonventre, E. J., Doyle, T. B., Du, Q., Duncan, L., Morris, T. W., Roche, E. D., Yan, D., Lynch, A. S. (2008). In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Studies of the Mode of Action in Staphylococcus aureus. Antimicrob. Agents Chemother. 52: 2313-2323 [Abstract] [Full Text]  
  • Butler, M. M., LaMarr, W. A., Foster, K. A., Barnes, M. H., Skow, D. J., Lyden, P. T., Kustigian, L. M., Zhi, C., Brown, N. C., Wright, G. E., Bowlin, T. L. (2007). Antibacterial Activity and Mechanism of Action of a Novel Anilinouracil-Fluoroquinolone Hybrid Compound. Antimicrob. Agents Chemother. 51: 119-127 [Abstract] [Full Text]  
  • Bronstein, J. C., Olson, S. L., LeVier, K., Tomilo, M., Weber, P. C. (2004). Purification and Characterization of Recombinant Staphylococcus haemolyticus DNA Gyrase and Topoisomerase IV Expressed in Escherichia coli. Antimicrob. Agents Chemother. 48: 2708-2711 [Abstract] [Full Text]  
  • Aubry, A., Pan, X.-S., Fisher, L. M., Jarlier, V., Cambau, E. (2004). Mycobacterium tuberculosis DNA Gyrase: Interaction with Quinolones and Correlation with Antimycobacterial Drug Activity. Antimicrob. Agents Chemother. 48: 1281-1288 [Abstract] [Full Text]  
  • Dandliker, P. J., Pratt, S. D., Nilius, A. M., Black-Schaefer, C., Ruan, X., Towne, D. L., Clark, R. F., Englund, E. E., Wagner, R., Weitzberg, M., Chovan, L. E., Hickman, R. K., Daly, M. M., Kakavas, S., Zhong, P., Cao, Z., David, C. A., Xuei, X., Lerner, C. G., Soni, N. B., Bui, M., Shen, L. L., Cai, Y., Merta, P. J., Saiki, A. Y. C., Beutel, B. A. (2003). Novel Antibacterial Class. Antimicrob. Agents Chemother. 47: 3831-3839 [Abstract] [Full Text]  
  • Nilius, A. M., Shen, L. L., Hensey-Rudloff, D., Almer, L. S., Beyer, J. M., Balli, D. J., Cai, Y., Flamm, R. K. (2003). In Vitro Antibacterial Potency and Spectrum of ABT-492, a New Fluoroquinolone. Antimicrob. Agents Chemother. 47: 3260-3269 [Abstract] [Full Text]  
  • Hiasa, H., Shea, M. E., Richardson, C. M., Gwynn, M. N. (2003). Staphylococcus aureus Gyrase-Quinolone-DNA Ternary Complexes Fail to Arrest Replication Fork Progression in Vitro. EFFECTS OF SALT ON THE DNA BINDING MODE AND THE CATALYTIC ACTIVITY OF S. AUREUS GYRASE. J. Biol. Chem. 278: 8861-8868 [Abstract] [Full Text]  
  • Wu, P., Lawrence, L. E., Denbleyker, K. L., Barrett, J. F. (2001). Mechanism of Action of the Des-F(6) Quinolone BMS-284756 Measured by Supercoiling Inhibition and Cleavable Complex Assays. Antimicrob. Agents Chemother. 45: 3660-3662 [Abstract] [Full Text]